A$4.8 -0.0 -0.6%
Last Trade - 26/02/21
| Market Cap | £535.4m |
| Enterprise Value | £670.8m |
| Revenue | £176.9m |
| Position in Universe | 294th / 1832 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 30th Jun | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 151.4 | 168 | 180.1 | 189.7 | 232.4 | 275.6 | 348.4 | 370.9 | +12.7% | ||
| +37.1 | +90.7 | -2.7 | +4.7 | +17.9 | +0.8 | +36.9 | +8.33 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Integral Diagnostics Limited is an Australia-based healthcare services company. The Company is principally engaged in providing diagnostic imaging services to general practitioners, medical specialists and allied health professionals (referrers) and their patients. The Company offers its services using its three brands, which include Lake Imaging (Victoria), South Coast Radiology (Queensland) and Global Diagnostics (Western Australia). The Company's integrated network provides communication, which allows physicians to access images at any time from any location. Global Diagnostics provide patients in rural and regional communities its diagnostic imaging services. South Coast Radiology provides medical imaging services and patient care to Gold Coast and Tweed communities. The Company's subsidiaries include Lake Imaging Pty Ltd, Radploy Pty Ltd, Global Diagnostics (Australia) Pty Ltd, SCR Corporate Pty Ltd and RAD Corporate Pty Ltd.
| Last Annual | June 30th, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | April 29, 2008 |
| Public Since | October 21, 2015 |
| No. of Shareholders: | 3,892 |
| No. of Employees: | n/a |
| Sector | Healthcare |
| Industry | Healthcare Providers & Services |
| Index | S&P/ASX All Ordinaries , S&P/ASX 300 , ASX Small Ordinaries , |
| Exchange | Australian Stock Exchange - SEATS |
| Shares in Issue | 198,545,113 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | Suite 902 Level 9 45 William Street, MELBOURNE, 3051, Australia |
| Web | https://www.integraldiagnostics.com.au/ |
| Phone | +61 3 53390704 |
| Contact | () |
| Auditors | PricewaterhouseCoopers |
As of 26/02/21, shares in Integral Diagnostics are trading at A$4.8, giving the company a market capitalisation of £535.4m. This share price information is delayed by 15 minutes.
Shares in Integral Diagnostics are currently trading at A$4.8 and the price has moved by 21.83% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Integral Diagnostics price has moved by 18.26% over the past year.
Of the analysts with advisory recommendations for Integral Diagnostics, there are there are currently 1 "buy" , 4 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Integral Diagnostics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Integral Diagnostics is scheduled to issue upcoming financial results on the following dates:
The Integral Diagnostics dividend yield is 1.98% based on the trailing twelve month period.
Last year, Integral Diagnostics paid a total dividend of 0.1, and it currently has a trailing dividend yield of 1.98%. Looking ahead, shares in Integral Diagnostics are due to go ex-dividend on 2021-03-01 and the next dividend pay date is 2021-04-06.
Integral Diagnostics are due to go ex-dividend on 2021-03-01 and the next dividend pay date is 2021-04-06. The historic dividend yield on Integral Diagnostics shares is currently 1.98%.
To buy shares in Integral Diagnostics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Integral Diagnostics are currently trading at A$4.8, giving the company a market capitalisation of £535.4m.
Here are the trading details for Integral Diagnostics:
Based on an overall assessment of its quality, value and momentum, Integral Diagnostics is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Integral Diagnostics are currently priced at A$4.8. At that level they are trading at 3.5% discount to the analyst consensus target price of 0.00.
Analysts covering Integral Diagnostics currently have a consensus Earnings Per Share (EPS) forecast of 0.192 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Integral Diagnostics. Over the past six months, the relative strength of its shares against the market has been 1.64%. At the current price of A$4.8, shares in Integral Diagnostics are trading at 16.14% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Integral Diagnostics PE ratio based on its reported earnings over the past 12 months is 28.01. The shares are currently trading at A$4.8.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Integral Diagnostics's management team is headed by:
Here are the top five shareholders of Integral Diagnostics based on the size of their shareholding:
